RxDoctor Payments Data

Ashok Chaudhary, MD

Cardiovascular Disease · New Brunswick, NJNPI 1407022460

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $109,097 of the $144,366 with a category attached, or 75.6%. 17 manufacturers reported payments, led by Edwards Lifesciences at 58.3% of the total. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$144,366in general payments, 2019–2025

Across 383 payments — averaging $376.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$84K
  • Biosense Webster, Inc.$35K
  • Medtronic$7K
  • Medical Device Business Services, Inc.$7K
  • Abbott$6K
  • Boston Scientific$2K
  • plus $4K from 11 others

What the payments were for

  • Consulting fees$109,09776%
  • Speaking & faculty fees$6,1004%
  • Travel & lodging$18,48913%
  • Food & beverage$10,6807%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$144,366 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$178,508
Medicare patients
1,884
Services billed
3,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$110,924
EntrestoSacubitril/Valsartan24$29,338
BrilintaTicagrelor47$29,046
JardianceEmpagliflozin20$21,398
Metoprolol Succinate135$2,387
Atorvastatin Calcium117$1,316
Rosuvastatin Calcium38$1,094
ClopidogrelClopidogrel Bisulfate70$777
Carvedilol48$516
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide25$331
Losartan Potassium52$293
Furosemide56$280
Lisinopril25$277
Amlodipine Besylate25$211
Spironolactone15$156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$110,924107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →